Brief: Aequus Pharma received positive feedback from FDA to pursue AQS1301

Aequus Pharmaceuticals

24/08/2017 14:02

Aug 24 (Reuters) - Aequus Pharmaceuticals Inc  AQS.V  
    * Aequus Pharmaceuticals Inc - received positive feedback 
from FDA to pursue abbreviated 505(b)(2) clinical pathway for 
co's AQS1301 
    * Aequus Pharmaceuticals- upon review of pre-IND submission, 
FDA agreed AQS1301 is suitable candidate for 505(b)(2) 
regulatory pathway for approval in U.S. 
 
Source text for Eikon:  ID:nCCNzjnJFa  
Further company coverage:  AQS.V  
 
 ((Bangalore.newsroom@thomsonreuters.com;))